title: Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone.
abstract: The optimal treatment approach for mixed phenotype acute leukemia (MPAL) remains unknown, and prognostic factors for treatment outcomes need to be identified. In this study, 66 patients diagnosed with MPAL according to criteria published by the WHO in 2008 were retrospectively assessed to evaluate the effectiveness of treatment and identify predictive variables. Five patients died of severe infection after the first induction chemotherapy, 29 received alloHSCT after induction (HSCT group), and 32 received only chemotherapy (chemotherapy group). The 3-year OS and DFS estimates for the entire cohort were 45% and 38%, respectively, and the 3-year OS differed significantly between the HSCT and chemotherapy-only groups (77% versus 16%). Using multivariate analyses, we identified disease burden as a prognostic factor for transplantation outcome, with the 3-year OS being 80% among patients who achieved remission and only 45% among patients in cases of nonremission. Our results indicate that alloHSCT after chemotherapy offers a survival advantage compared with chemotherapy only, and patients in remission before transplantation may experience a better outcome.
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Tian
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Liming
authors.initials: L
authors.lastname: Liu
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Lingzhi
authors.initials: L
authors.lastname: Yan
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Zhengming
authors.initials: Z
authors.lastname: Jin
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Tang
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Han
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Zhengzheng
authors.initials: Z
authors.lastname: Fu
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Huiying
authors.initials: H
authors.lastname: Qiu
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China.
authors.forename: Aining
authors.initials: A
authors.lastname: Sun
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, China; Collaborative Innovation Center of Hematology, Soochow University, 188 Shizi Street, Suzhou 215006, China; Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006, China. Electronic address: wudepei@medmail.com.cn.
authors.forename: Depei
authors.initials: D
authors.lastname: Wu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality; D006801:Humans; D016130:Immunophenotyping; D060828:Induction Chemotherapy / Q000379:methods / Q000401:mortality; D007938:Leukemia / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents
keywords: Allogeneic hematopoietic stem cell transplantation; Chemotherapy; Mixed phenotype acute leukemia; Prognosis